Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser H. Hanna, Paul A. Bunn, Miklos Pless et al.|Journal of Clinical Oncology|2004Cited by 2.4k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialRobert Pirker, U. Gatzemeier, Jose R. Pereira et al.|The Lancet|2009Cited by 1.4k
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupFrank V. Fossella, Chandra P. Belani, Jose R. Pereira et al.|Journal of Clinical Oncology|2003Cited by 943
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Kenneth J. O’Byrne, Jose R. Pereira et al.|The Lancet Oncology|2011Cited by 574